Literature DB >> 28473952

Liver-allocation policies for patients affected by HCC in Europe.

Luciano De Carlis1,2, Stefano Di Sandro2,3, Leonardo Centonze2, Andrea Lauterio2, Vincenzo Buscemi2,3, Riccardo De Carlis2,3, Fabio Ferla2, Raffaella Sguinzi2, Stefano Okolicsanyi1, Luca Belli2, Mario Strazzabosco1,4.   

Abstract

The main goal of organ allocation systems is to guarantee an equal access to the limited resource of liver grafts for every patients on the waiting list, balancing between the ethical principles of equity, utility, benefit, need, and fairness. The European heath care scenario is very complex, as it is essentially decentralized and each Nation and Regions inside the nation, operate on a significant degree of autonomy. Furthermore the epidemiology of liver diseases and HCC, which is different among European countries, clearly inpacts on indications and priorities. The aims of this review are to analyze liver allocation policies for hepatocellular carcinoma, among different European. The European area considered for this analysis included 5 macro-areas or countries, which have similar policies for liver sharing and allocation: Centro Nazionale Trapianti (CNT) in Italy; Eurotransplant (Germany, the Netherlands, Belgium, Luxembourg, Austria, Hungary, Slovenia, and Croatia); Organizacion Nacional de Transplantes (ONT) in Spain; Etablissement français des Greffes (EfG) in France; NHS Blood & Transplant (NHSBT) in the United Kingdom and Ireland; Scandiatransplant (Sweden, Norway, Finland, Denmark, and Iceland). Each identified area, as network for organ sharing in Europe, adopts an allocation system based either on a policy center oriented or on a policy patient oriented. Priorization of patients affected by HCC in the waiting list for deceased donors liver transplant worldwide is dominated by 2 main principles: urgency and utility. Despite the absence of a common organs allocation policy over the Eurpean countries, long-term survival patients listed for transplant due to HCC are comparable to the long-term survival reported in the UNOS register. However, as the principles of allocation are being re-discussed and new proposals emerge, and the epidemiology of liver disease changes, an effort toward a common system is highly advisable.

Entities:  

Keywords:  Europe; Hepatocellular Carcinoma; allocation policy; liver transplantation

Year:  2016        PMID: 28473952      PMCID: PMC5410888          DOI: 10.1007/s40472-016-0117-6

Source DB:  PubMed          Journal:  Curr Transplant Rep


  24 in total

1.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

2.  Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR).

Authors:  René Adam; Vincent Karam; Valérie Delvart; John O'Grady; Darius Mirza; Jurgen Klempnauer; Denis Castaing; Peter Neuhaus; Neville Jamieson; Mauro Salizzoni; Stephen Pollard; Jan Lerut; Andreas Paul; Juan Carlos Garcia-Valdecasas; Fernando San Juan Rodríguez; Andrew Burroughs
Journal:  J Hepatol       Date:  2012-05-16       Impact factor: 25.083

3.  Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence.

Authors:  C Toso; G Mentha; P Majno
Journal:  Am J Transplant       Date:  2011-08-10       Impact factor: 8.086

4.  V Consensus Meeting of the Spanish Society for Liver Transplant on high-risk recipients, immunosupression scenarios and management of hepatocarcinoma on the transplant waiting list.

Authors:  Fernando Pardo; José Antonio Pons; Javier Briceño
Journal:  Cir Esp       Date:  2015-07-15       Impact factor: 1.653

Review 5.  Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.

Authors:  Claire Francoz; Jacques Belghiti; Denis Castaing; Olivier Chazouillères; Jean-Charles Duclos-Vallée; Christophe Duvoux; Jan Lerut; Yves-Patrice Le Treut; Richard Moreau; Ameet Mandot; Georges Pageaux; Didier Samuel; Dominique Thabut; Dominique Valla; François Durand
Journal:  Liver Transpl       Date:  2011-10       Impact factor: 5.799

6.  Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation?

Authors:  Luciano De Carlis; Stefano Di Sandro; Alessandro Giacomoni; Abdallah Slim; Andrea Lauterio; Iacopo Mangoni; Plamen Mihaylov; Vincenzo Pirotta; Paolo Aseni; Antonio Rampoldi
Journal:  J Clin Gastroenterol       Date:  2012-01       Impact factor: 3.062

7.  The survival benefit of liver transplantation.

Authors:  Robert M Merion; Douglas E Schaubel; Dawn M Dykstra; Richard B Freeman; Friedrich K Port; Robert A Wolfe
Journal:  Am J Transplant       Date:  2005-02       Impact factor: 8.086

8.  Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era.

Authors:  Matteo Ravaioli; Gian Luca Grazi; Giorgio Ercolani; Matteo Cescon; Massimo Del Gaudio; Matteo Zanello; Giorgio Ballardini; Giovanni Varotti; Gaetano Vetrone; Francesco Tuci; Augusto Lauro; Giovanni Ramacciato; Antonio Daniele Pinna
Journal:  Transplantation       Date:  2006-02-27       Impact factor: 4.939

9.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Authors:  George N Ioannou; James D Perkins; Robert L Carithers
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

10.  Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach.

Authors:  Vincenzo Mazzaferro
Journal:  Hepatology       Date:  2016-02-26       Impact factor: 17.425

View more
  5 in total

1.  Liver transplantation for hepatocellular carcinoma: alpha-fetoprotein should be included in selection criteria.

Authors:  Hans-Christian Pommergaard
Journal:  Transl Gastroenterol Hepatol       Date:  2018-12-11

2.  A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma.

Authors:  Yi Wei; Zheng Ye; Yuan Yuan; Zixing Huang; Xiaocheng Wei; Tong Zhang; Shang Wan; Hehan Tang; Xiaopeng He; Bin Song
Journal:  Liver Cancer       Date:  2020-04-14       Impact factor: 11.740

3.  Centralization of Major Trauma Influences Liver Availability for Transplantation in Northern Italy: Lesson Learned from COVID-19 Pandemic.

Authors:  Michele Altomare; Andrea Chierici; Francesco Virdis; Andrea Spota; Stefano Piero Bernardo Cioffi; Shir Sara Bekhor; Luca Del Prete; Elisa Reitano; Marco Sacchi; Federico Ambrogi; Osvaldo Chiara; Stefania Cimbanassi
Journal:  J Clin Med       Date:  2022-06-24       Impact factor: 4.964

4.  Liver Grafts with Major Extended Donor Criteria May Expand the Organ Pool for Patients with Hepatocellular Carcinoma.

Authors:  Vladimir J Lozanovski; Larissa T B Kerr; Elias Khajeh; Omid Ghamarnejad; Jan Pfeiffenberger; Katrin Hoffmann; De-Hua Chang; Markus Mieth; Thomas Longerich; Oliver Strobel; Karl Heinz Weiss; Markus W Büchler; Arianeb Mehrabi
Journal:  J Clin Med       Date:  2019-10-15       Impact factor: 4.241

5.  Hepatocellular carcinoma recurrence in living and deceased donor liver transplantation: a systematic review and meta-analysis.

Authors:  Hai-Ming Zhang; Yue-Xian Shi; Li-Ying Sun; Zhi-Jun Zhu
Journal:  Chin Med J (Engl)       Date:  2019-07-05       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.